Skip to main content

After big buyout, team looks to lead hepatitis B, NASH drug maker to $100M IPO

Much of the team that led Alios — without a "g" — to aa $1.8 billion acquisition now is back with Aligos.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.